Intellia Therapeutics, Inc NTLA
Key Stats
- Today's Range
- $10.60 – $11.19
- 50-Day Range
- $10.15 – $18.48
- 52-Week Range
- $7.95 – $28.25
- Volume
- 2.65 million shs
- Average Volume
- 4.58 million shs
- Market Cap
- $1.49 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.40
- Price / Sales
- 22.58
Short Interest
- Short Interest
- 2.44%
- Days to Cover
- 5.35
Financials (TTM)
- Revenue
- $66.09 million
- Net Income
- $-394,596,000
- Net Margin
- -597.04%
- Return on Equity
- -63.55%
- Debt-to-Equity
- —
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.